Guerbet: Financial agenda for 2024

2024-01-15

财报

Financial agenda for 2024

Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.

Publications calendar

2023 ANNUAL REVENUE

February 08, 2024, after trading

2023 ANNUAL RESULTS

March 20, 2024, after trading

2024 1ST QUARTER REVENUE

April 25, 2024, after trading

ANNUAL SHAREHOLDERS’ MEETING

May 24, 2024

2024 2ND QUARTER REVENUE

July 25, 2024, after trading

2024 FIRST HALF RESULTS

September 25, 2024, after trading

2024 3RD QUARTER REVENUE

October 24, 2024, after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.

Contacts :

Guerbet

Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / jerome.estampes@guerbet.com

Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.com

Actifin

Marianne Py, Financial Communication + 33.1.80.48.25.31 / marianne.py@seitosei-actifin.com

Jennifer Jullia, Media Relations +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

Attachment

Guerbet_PR Agenda 2024

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构